Edition:
India

AngioDynamics Inc (ANGO.OQ)

ANGO.OQ on NASDAQ Stock Exchange Global Select Market

15.01USD
17 Oct 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$15.01
Open
$14.74
Day's High
$15.02
Day's Low
$14.74
Volume
107,575
Avg. Vol
78,982
52-wk High
$25.45
52-wk Low
$13.77

Latest Key Developments (Source: Significant Developments)

Angiodynamics Q1 Adjusted Earnings Per Share $0.08
Thursday, 3 Oct 2019 

AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.08.Q1 LOSS PER SHARE $0.03 FROM CONTINUING OPERATIONS.Q1 SALES $66 MILLION VERSUS REFINITIV IBES ESTIMATE OF $67.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.04 -- REFINITIV IBES DATA.SEES FY 2020 SALES $280 MILLION TO $286 MILLION.NOW EXPECTS FY ADJUSTED EARNINGS PER SHARE IN RANGE OF $0.10 TO $0.15.AS OF AUGUST 31, 2019, COMPANY HAD $83.6 MILLION IN CASH AND CASH EQUIVALENTS AND NO DEBT OUTSTANDING.FOREIGN CURRENCY TRANSLATION DID NOT HAVE A SIGNIFICANT IMPACT ON COMPANY'S SALES IN QUARTER.  Full Article

Angiodynamics Acquires Eximo Medical, Ltd. And Its Innovative 355Nm Laser Atherectomy Technology
Thursday, 3 Oct 2019 

AngioDynamics Inc ::ANGIODYNAMICS ACQUIRES EXIMO MEDICAL, LTD. AND ITS INNOVATIVE 355NM LASER ATHERECTOMY TECHNOLOGY.ANGIODYNAMICS INC - TRANSACTION IS BEING FUNDED EXCLUSIVELY THROUGH USE OF CASH ON HAND.ANGIODYNAMICS INC - TRANSACTION IS BEING FUNDED EXCLUSIVELY THROUGH USE OF CASH ON HAND.ANGIODYNAMICS INC - DEAL FOR $46 MILLION IN UP-FRONT CONSIDERATION WITH UP TO $20 MILLION OF CONTINGENT CONSIDERATION.  Full Article

AngioDynamics To Sell Namic Fluid Management Business To Medline Industries For $167.5 Mln
Thursday, 18 Apr 2019 

April 17 (Reuters) - AngioDynamics Inc ::PRESS RELEASE - ANGIODYNAMICS ANNOUNCES AGREEMENT TO SELL NAMIC® FLUID MANAGEMENT BUSINESS TO MEDLINE INDUSTRIES, INC. FOR $167.5 MILLION.ANGIODYNAMICS INC - INTENDS TO USE NET CASH PROCEEDS OF APPROXIMATELY $160.0 MILLION TO PAY DOWN ALL OUTSTANDING DEBT.ANGIODYNAMICS INC - CASH BALANCE OF APPROXIMATELY $74.0 MILLION WILL BE USED TO SUPPORT STRATEGIC INVESTMENTS IN COMPANY'S EXISTING PORTFOLIO.  Full Article

Angiodynamics Receives FDA Approval To Initiate Nanoknife Direct Clinical Study
Monday, 1 Apr 2019 

April 1 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS RECEIVES FDA APPROVAL TO INITIATE NANOKNIFE® DIRECT CLINICAL STUDY FOR THE TREATMENT OF STAGE III PANCREATIC CANCER.ANGIODYNAMICS INC - AS PART OF DIRECT CLINICAL STUDY, ANGIODYNAMICS IS LAUNCHING ANGIODIRECT.COM TO FACILITATE ENROLLMENT OF PARTICIPANTS.  Full Article

AngioDynamics Wins Patent Infringement Dispute With Bard
Friday, 8 Mar 2019 

March 8 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS WINS PATENT INFRINGEMENT DISPUTE WITH BARD.ANGIODYNAMICS INC - U.S. COURT DISMISSED BARD'S SUIT ALLEGING THAT CERTAIN OF CO'S IMPLANTABLE PORT PRODUCTS INFRINGED THREE BARD PATENTS.  Full Article

AngioDynamics Q1 Adjusted Earnings Per Share $0.16
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2019 FIRST QUARTER FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.16.Q1 GAAP LOSS PER SHARE $0.01.SEES FY 2019 SALES $354 MILLION TO $359 MILLION.Q1 SALES $85.3 MILLION VERSUS I/B/E/S VIEW $84 MILLION.Q1 EARNINGS PER SHARE VIEW $0.18 -- THOMSON REUTERS I/B/E/S.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $0.82 TO $0.86.CURRENCY DID NOT HAVE SIGNIFICANT IMPACT ON CO'S SALES IN QUARTER.SAYS UPDATING FINANCIAL GUIDANCE TO REFLECT BIOSENTRY AND RADIADYNE ACQUISITIONS AND PAYMENT MADE TO DOJ.  Full Article

Angiodynamics Inc Sees FY 2019 Rev $348 Mln To $353 Mln
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - AngioDynamics Inc ::SEES FY 2019 REVENUE $348 MILLION TO $353 MILLION.FY2019 REVENUE VIEW $345.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

AngioDynamics Q3 Earnings Per Share $0.37
Thursday, 29 Mar 2018 

March 29 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.25.Q3 GAAP EARNINGS PER SHARE $0.37.Q3 SALES $83.9 MILLION VERSUS I/B/E/S VIEW $84.8 MILLION.Q3 EARNINGS PER SHARE VIEW $0.19 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 SALES $345 MILLION TO $350 MILLION.SEES 2018 ADJUSTED EARNINGS PER SHARE $0.70 TO $0.74.ANGIODYNAMICS - ‍ EXPECTS ITS ADJUSTED EARNINGS PER SHARE IN RANGE OF $0.64 TO $0.68, EXCLUDING ANY IMPACT FROM 2017 TAX REFORM ACT​ FOR FY 2018.FY2018 EARNINGS PER SHARE VIEW $0.71, REVENUE VIEW $346.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic Cancer
Thursday, 25 Jan 2018 

Jan 24 (Reuters) - Angiodynamics Inc ::ANGIODYNAMICS RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE NANOKNIFE® SYSTEM FOR THE TREATMENT OF STAGE III PANCREATIC CANCER.ANGIODYNAMICS INC - ‍FDA GRANTED EXPEDITED ACCESS PATHWAY DESIGNATION TO COMPANY'S NANOKNIFE SYSTEM​.  Full Article

AngioDynamics Says U.S. Tax Reform To Have Impact Of $0.02- $0.04 On Non-GAAP Adjusted EPS In FY 2018
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS SAYS U.S. TAX REFORM ACT TO HAVE AN IMPACT IN RANGE OF $0.02- $0.04 ON NON-GAAP ADJUSTED EPS IN FY 2018 -SEC FILING.  Full Article